Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types

H. van der Wijngaart, L.R. Hoes, J.M.V. Henegouwen, D.L. van der Velden, L.J. Zeverijn, P. Roepman, E. van Werkhoven, W.W.J. de Leng, A.M.L. Jansen, N. Mehra, D.G.J. Robbrecht, M. Labots, D.J.A. de Groot, A. Hoeben, P. Hamberg, H. Gelderblom, E.E. Voest, H.M.W. Verheul*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Fingerprint

Dive into the research topics of 'Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

INIS

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology